16 Dec Exact Sciences announces pricing of public offering of common stock
Exact Sciences Corporation (NASDAQ: EXAS) today announced the pricing of the public offering of 4,000,000 common shares previously sold to Jefferies LLC and Robert W. Baird & Co. Incorporated, as underwriters of the offering. The common shares will be sold at a public offering price of $25.75 per share. The Company has also granted the underwriters an option to purchase up to 600,000 additional shares. The offering is expected to close on or about December 19, 2014, subject to customary closing conditions.
The Company intends to use the net proceeds of this offering to fund expansion of Cologuard® commercialization activities, to fund product development efforts, and for general corporate and working capital purposes.
Jefferies LLC and Robert W. Baird & Co. Incorporated acted as the underwriters for the offering. A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and is effective. A copy of the prospectus supplement and prospectus relating to these securities may be obtained by contacting (a) Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling 877-547-6340, or by e-mailing Prospectus_Department@Jefferies.com, (b) Robert W. Baird & Co. Incorporated, Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, or by calling 800-792-2473, or by e-mailing email@example.com, or (c) the Internet site of the SEC at http://www.sec.gov.
About Exact Sciences
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.